175 Years of MAQUET: Leading Medical Technology Company Sets Standards in International Health Care Markets

Jan 29, 2014, 08:47 ET from MAQUET Holding B.V. & Co. KG

DUBAI, UAE, January 29, 2014 /PRNewswire/ --

Worldwide leader for innovative therapy solutions and integrated hospital projects celebrates 175 years of medical excellence at ARAB HEALTH

With 175 years history, MAQUET is one of the most established and, at the same time, dynamic medical technology companies in the world. The company celebrates its anniversary year with a journey through time at this year's ARAB HEALTH in Dubai.

     (Logo: http://photos.prnewswire.com/prnh/20140129/666982-a )

     (Photo: http://photos.prnewswire.com/prnh/20140129/666982-b )

The innovative history of MAQUET is reflected in the booth concept: The company has made remarkable contributions to the development of therapeutic medical solutions throughout its long evolution. The stand shows how the competencies of the company have developed and expanded out over time. From operating room equipment to vascular surgery, respiration and anesthesia to sectors such as cardiac assist, invasive cardiac surgery and the use of extracorporeal assistance systems which have revolutionized the local and global transportation options for intensive care patients in a life-threatening state.

Innovation is the basis for success

Innovations form the foundation for profitable and sustainable growth in international health markets. Approximately 600 staff members are employed in eight globally distributed development centers. Around eight percent of the turnover is re-invested in innovation projects; for example, the new SERVO-U™ ventilation platform that responds to the individual respiratory needs of each patient.

Medical and technical innovations play an increasingly larger role in the international health system. But in times of limited budgets, particular focus is placed on the economic sustainability of investment and therapies. "The requirements of our customers have changed," says Heinz Jacqui, Chief Executive Officer, MAQUET Holding. "Hospitals are no longer interested in clinical relevance only, but they are also focused on the influence that the product has on the return on investment. We see ourselves as trendsetters and experts for both aspects."


MAQUET products and therapies have always aimed to set new standards in medical technology and to achieve better patient outcomes as well as clinical and economical benefits. "But to comprehensively address the changing market demands with an even stronger focus on sustainability and economic benefits, we have implemented a new organization for the Region WEMEA (Western Europe, Middle East and Africa) in 2013", says Serge Exshaw, Vice President MAQUET Holding and Head of Global Sales and Marketing. This new Regional structure will ensure higher sales support and stronger campaign capability. "And above all, it will enhance Cross Divisional Selling to better address our customer call points", emphasizes Exshaw. Going into 2014, local country organizations will be structured accordingly to consolidate customer requirements for advanced product developments in the future.

Challenges in the implementation of complex hospital projects

The operating room generates essential revenue for the hospital. Optimized processes and minimized downtimes are the main elements of efficient utilization. The core competencies of MAQUET are overall solutions for operating rooms, intensive care and recovery areas, as well as the central sterilization and other sensitive areas of a hospital. As a pioneer in the implementation of complex projects, MAQUET supports clinics in the realization of tailored solutions, from consulting to design, planning, production and installation, as well as initial operation. The concept has drawn considerable attention worldwide. "Thanks to our long-time experience and deep expertise, we are able to set superior standards in the health care environment by implementing ambitious and complex hospital projects in the region Middle East," says Salah Malek, Vice President Middle East, MAQUET Middle East FZ-LCC.

Dynamic development into global player

Originally MAQUET focused on the surgical infrastructure of hospitals; this made the company a global player for innovative therapy solutions and integrated hospital projects for operating rooms and intensive care units. The intelligent integration of new fields of business has enhanced the product portfolio and is linked to healthy organic growth. Today, MAQUET is a leading global provider in a position to almost completely fit operating departments with products from the surgical workplaces, intensive care and cardiovascular sectors. Since its acquisition by the Swedish GETINGE Group in 2000, MAQUET has seen rapid growth, as reflected in employees and turnover. Within a decade, the number of employees has multiplied fivefold to more than 6,550, and the company was able to record an enormous growth in turnover from € 155 million to € 1.54 billion!

More pictures are available under:

http://ots.de/2194ab (Heinz Jacqui, Chief Executive Officer, MAQUET Holding)

http://photos.prnewswire.com/prnh/20140122/666446 (Serge Exshaw, Vice President MAQUET Holding and Head of Global Sales and Marketing)

Visit MAQUET at the ARAB HEALTH 2014, Sheikh Saeed Hall 2, Stand S2G30


MAQUET has been a trusted partner of hospitals and doctors for more than 175 years. The company is also a world-leading provider of medical systems that meet the highest requirements for medically challenging interventions. At the same time, these systems exceed the expectations of the hospital teams that are responsible for the care of patients. MAQUET designs, develops and sells innovative treatment solutions and infrastructure functions for extremely demanding hospital departments, including operating rooms, hybrid operating rooms, catheter laboratories and intensive care units as well as intra- and inter-hospital patient transportation.

With its headquarters in Rastatt, Germany, MAQUET is the largest subsidiary of the GETINGE Group, which is listed on the stock exchange. With over € 1.54 billion in 2013, MAQUET exceeded half of the €  2.92 billion annual turnover of the group. MAQUET employs more than 6,550 members of staff at 45 international sales and service organizations and maintains a network of about 300 sales partners. For more information, visit http://www.maquet.com.

Maquet - The Gold Standard.

G005 Nucleotide Complex,
Dubai Biotechnology & Research Park, P.O. Box 214742
Dubai, United Arab Emirates